In tumour cells, the identification of MK2 as an alternative cell cycle checkpoint, mediating resistance to apoptosis upon p53 mutation, has led to the emergence of MK2 as a promising target for combinatorial cancer therapies26. Here, MAPKAPK2 is linked to cancer.